CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Mechanical circulatory support devices for acute right ventricular failure Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

Review ArticleVolume 76, Issue 6, August 2020

JOURNAL:J Am Coll Cardiol. Article Link

Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel

JE Wilcox, JC Fang, KB Margulies et al. Keywords: heart failure with recovered ejection fraction; myocardial recovery

ABSTRACT

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction. A growing body of evidence suggests that even among patients who experience a complete normalization of LV ejection fraction, a significant proportion will develop recurrent LV dysfunction accompanied by recurrent heart failure events. This has led to intense interest in understanding how to manage patients with heart failure with recovered ejection fraction (HFrecEF). Because of the lack of a standard definition for HFrecEF, and the paucity of clinical data with respect to the natural history of HFrecEF patients, there are no current guidelines on how these patients should be followed up and managed. Accordingly, thisJACCScientific Expert Panel reviews the biology of reverse LV remodeling and the clinical course of patients with HFrecEF, as well as provides guidelines for defining, diagnosing, and managing patients with HFrecEF.